Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators
- PMID: 10887103
Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators
Abstract
Although persons with hemophilia are known to be at increased risk of death, no studies have examined the source of medical care and other personal characteristics for associations with mortality. To determine death rates and to identify causes of death and predictors of mortality, we studied a cohort comprised of all hemophilic males identified by a six-state surveillance system. Data were obtained by medical record review of contacts with physicians, hemophilia treatment centers (HTCs), and other sources of care during 1993-1995 and from death certificates. Factors examined included age, race, state of residence, health insurance type, medical care source, hemophilia type/severity, presence of inhibitor, liver disease, HIV infection, and AIDS. A total of 2950 subjects were followed for an average of 2.6 years. Their median age was 22 years; 73% were white, 79% had hemophilia A, 42% had severe disease, and 67% had visited an HTC. During 7575 person years (PYs) of observation, 236 persons died-an age-adjusted mortality rate of 40.4 deaths/1000 PYs; 65% of deaths were HIV related. In addition to age, factors independently associated with increased risk of death (relative risk, P value) were the following: AIDS (33.5, <.001); HIV infection (4.7, <.001); liver disease (2.4, <.001); and Medicare/Medicaid insurance (1.4,. 01). Those persons who had received care in an HTC had a significantly decreased risk of death (0.6,.002). Although HIV infection and the presence of severe liver disease remain strong predictors of mortality, survival is significantly greater among hemophilics who receive medical care in HTCs. (Blood. 2000;96:437-442)
Similar articles
-
Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States.Am J Hematol. 2001 Apr;66(4):229-40. doi: 10.1002/ajh.1050. Am J Hematol. 2001. PMID: 11279632
-
Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion.J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):89-97. doi: 10.1097/00042560-199809010-00014. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9732075
-
Changes in longevity and causes of death among persons with hemophilia A.Am J Hematol. 1994 Feb;45(2):112-21. doi: 10.1002/ajh.2830450204. Am J Hematol. 1994. PMID: 8141117
-
Acquired immune deficiency syndrome associated with hemophilia in the United States.Instr Course Lect. 1989;38:357-65. Instr Course Lect. 1989. PMID: 2649586 Review.
-
AIDS and hemophilia: experience in the La Paz Hemophilia Center.Haemostasis. 1992;22(5):281-92. doi: 10.1159/000216336. Haemostasis. 1992. PMID: 1362177 Review.
Cited by
-
Current Status and Challenges in Delivering Comprehensive Care for Patients with Hemophilia.J Blood Med. 2023 Dec 15;14:629-637. doi: 10.2147/JBM.S446204. eCollection 2023. J Blood Med. 2023. PMID: 38125786 Free PMC article. Review.
-
Clinical perspectives of emerging pathogens in bleeding disorders.Lancet. 2006 Jan 21;367(9506):252-61. doi: 10.1016/S0140-6736(06)68036-7. Lancet. 2006. PMID: 16427495 Free PMC article. Review.
-
Perioperative Outcomes of Patients with Bleeding Disorders Undergoing Major Surgery at an Academic Hemophilia Treatment Center.Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231165056. doi: 10.1177/10760296231165056. Clin Appl Thromb Hemost. 2023. PMID: 36972481 Free PMC article.
-
Novel treatments for hemophilia through rebalancing of the coagulation cascade.Pediatr Blood Cancer. 2021 May;68(5):e28934. doi: 10.1002/pbc.28934. Epub 2021 Feb 12. Pediatr Blood Cancer. 2021. PMID: 33577709 Free PMC article. Review.
-
Acute Myocardial Infarction in Hemophilia A with HIV and Hyperhomocysteinemia- A Rare Case Report.Cardiovasc Hematol Disord Drug Targets. 2022;22(1):3-5. doi: 10.2174/1871529X22666220126122458. Cardiovasc Hematol Disord Drug Targets. 2022. PMID: 35081897
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical